Longevity biotech draws $3.74bn in Q1 2026 as leaders eye 150-year lifespans

September 27, 2026 at 08:48 PM2 min

This digest was compiled by AI from multiple sources — links to the originals are below.

Longevity biotechnology companies raised approximately $3.74 billion in the first quarter of 2026, according to a Forbes report cited by Al Jazeera. The surge follows public remarks by Russian President Vladimir Putin and Chinese President Xi Jinping on advances in organ transplantation and predictions of 150-year human lifespans this century. The field aims to treat biological mechanisms of age-related diseases to extend healthspan and lifespan.

Key Facts

Longevity biotech companies raised approximately $3.74 billion in the first quarter of 2026.
Russian President Vladimir Putin and Chinese President Xi Jinping discussed organ transplantation and predictions of 150-year human lifespans this century.
Russia has reportedly directed billions of dollars toward organ transplantation research and regenerative medicine.
Cancer immunotherapy Keytruda is one of the world's best-selling drugs and an example of biotechnology's success in healthcare.
The Epic of Gilgamesh, the world's oldest surviving literary epic, contains poems about the search for immortality.

Investment Surge

In the first quarter of 2026, longevity biotech companies raised approximately $3.74 billion. A recent Forbes article called longevity biotech the billionaire's next big bet after artificial intelligence. Russia has reportedly directed billions of dollars toward organ transplantation research and regenerative medicine.

Scientific Foundations

Longevity biotechnology aims to treat the underlying biological mechanisms of age-related diseases to increase healthspan or lifespan. Biotechnology uses biological systems themselves to tackle medical problems, unlike traditional pharmaceutical research that designs chemicals to interact with biological targets. Cancer immunotherapy Keytruda, one of the world's best-selling drugs, exemplifies biotechnology's success in healthcare. Academic journals dedicated to ageing and longevity now exist.

Historical Pursuit

The Epic of Gilgamesh, the world's oldest surviving literary epic, contains poems detailing Gilgamesh's search for immortality after the death of his companion Enkidu. China's first emperor, Qin Shi Huang, reportedly died from suspected mercury poisoning in his search for an immortality elixir. In the 1920s, Alexander Bogdanov pioneered blood transfusions from the young to the old as a method to slow ageing, though there is little proof it worked.